Loading...
Thumbnail Image
Publication

Medicare Part D: Drug Pricing and Manufacturer Windfalls

House Committee on Oversight and Government Reform
Abstract
The House Committee on Oversight and Government Reform compares drug prices under the Medicare Part D program with those under traditional Medicaid, revealing that Medicare Part D pays on average 30% more for drugs than Medicaid. The prices paid for drugs under Medicare Part D are found to be significantly higher than those paid by Medicaid, leading to a windfall of over $3.7 billion for drug manufacturers in the first two years of the Medicare Part D program. The report focuses on the costs to taxpayers for providing drug coverage to six million "dual eligible" beneficiaries, who qualify for both Medicare and Medicaid.
Date
2008-07-24
Document Type
House Majority Staff Report
Serial Number
Document Length
15 pages
Congress
110
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs
Related Hearings
Press Releases and Contextual Information
https://web.archive.org/web/20090101101402/http://oversight.house.gov/story.asp?id=2103